| London Jobs |
| Manchester Jobs |
| Liverpool Jobs |
| Nottingham Jobs |
| Birmingham Jobs |
| Cambridge Jobs |
| Glasgow Jobs |
| Bristol Jobs |
| Wales Jobs |
| London Jobs |
| Manchester Jobs |
| Liverpool Jobs |
| Nottingham Jobs |
| Birmingham Jobs |
| Cambridge Jobs |
| Glasgow Jobs |
| Bristol Jobs |
| Wales Jobs |
| Oil & Gas Jobs |
| Banking Jobs |
| Construction Jobs |
| Top Management Jobs |
| IT - Software Jobs |
| Medical Healthcare Jobs |
| Purchase / Logistics Jobs |
| Sales |
| Ajax Jobs |
| Designing Jobs |
| ASP .NET Jobs |
| Java Jobs |
| MySQL Jobs |
| Sap hr Jobs |
| Software Testing Jobs |
| Html Jobs |
| Job Location | Cambridge |
| Education | Not Mentioned |
| Salary | Salary negotiable |
| Industry | Not Mentioned |
| Functional Area | Not Mentioned |
| Job Type | Permanent, full-time |
Are you a junior scientist or research technician from industry or academia with experience of working in a mammalian tissue culture, molecular biology or cell phenotyping laboratory Would you like to transfer into the next exciting chapter of a rapidly expanding research organisationThere is a competitive salary plus excellent annual leave allowance.We are looking for a motivated scientific professional with a Bachelor or Masters degree in cell biology, molecular biology or similar, plus at least 1 year of laboratory experience in a R&D team in industry or academic research lab. Practical experience of mammalian tissue culture, basic cell phenotyping and molecular biology techniques are required.Practical experience of mammalian tissue culture and basic cell phenotyping methods including Flow Cytometry is also essential for this role. Immune Cell functional assays is also highly desirable.If you also have practical experience with human pluripotent stem cell culture and differentiation or Genetic modification tools (recombinant viral vectors, CRISPR/Cas), then we would be particularly keen to hear from you.Due to the high interest expected in this role, if you do not possess the techniques listed, you will not be considered at this time.